Treatment of Paraneoplastic Cerebellar Degeneration

John E. Greenlee, MD

Address
1 Veterans Affairs Medical Center Salt Lake City, Salt Lake City, USA
2 Clinical Neuroscience Center, University of Utah, 175 North Medical Drive East, Salt Lake City, UT 84132, USA
Email: john.greenlee@hsc.utah.edu

Published online: 13 January 2013
© Springer Science+Business Media New York (outside the USA) 2013

Keywords Paraneoplastic • Paraneoplastic cerebellar degeneration • Breast neoplasms • Ovarian neoplasms • Uterine neoplasms • Fallopian carcinoma • Small cell cancer • Hodgkin’s disease • Lung neoplasms • Autoantibodies • T lymphocytes • Prednisone • Intravenous immunoglobulin G • Cyclophosphamide • Plasma exchange • Rituximab • Tacrolimus • Mycophenolate mofetil • Treatment

Opinion statement
Paraneoplastic cerebellar degeneration is an uncommon autoimmune disorder characterized clinically by progressive, ultimately incapacitating ataxia and pathologically by destruction of cerebellar Purkinje cells, with variable loss of other cell populations. The disorder is most commonly associated with gynecological and breast carcinomas, small cell carcinoma of the lung, and Hodgkin’s disease and in most cases comes on prior to identification of the underlying neoplasm. The hallmark of paraneoplastic cerebellar degeneration is the presence of an immune response reactive with intracellular proteins of Purkinje or other neurons or, less commonly, against neuronal surface antigens. Evidence-based treatment strategies for paraneoplastic cerebellar degeneration do not exist; and approaches to therapy are thus speculative. Diagnosis and treatment of the underlying neoplasm is critical, and characterization of the antibody response involved may assist in tumor diagnosis. Most investigators have initiated treatment with corticosteroids, plasma exchange, or intravenous immunoglobulin G. Cyclophosphamide, tacrolimus, rituximab, or possibly mycophenolate mofetil may warrant consideration in patients who fail to stabilize or improve on less aggressive therapies. Plasma exchange has been of questionable benefit when used alone but should be considered at initiation of treatment to achieve rapid lowering of circulating paraneoplastic autoantibodies. Because the course of illness is one of relentless neuronal destruction, time is of the essence in initiating treatment. Likelihood of clinical improvement in patients with longstanding symptoms and extensive neuronal loss is poor.

Introduction
Paraneoplastic cerebellar degeneration is a remote (non-metastatic) complication of cancer characterized clinically by progressive ataxia, often associated with vertigo, nausea, and nystagmus or opsoclusus [1–3]. The disorder is most frequently associated with adenocarcinomas of the ovaries, uterus, or adnexa, adenocarcinomas of the breast, and
small cell carcinoma of the lung (SCLC) [1, 4, 5] (Table 1). A smaller number of cases has been reported in association with Hodgkin’s disease, and rare cases have been reported with other malignancies [1, 6]. Paraneoplastic cerebellar degeneration may have its onset up to 5 years prior to cancer detection. Disease progression typically leads to complete incapacitation, the patient often being unable to sit without assistance, speak clearly, or assist in any aspects of his or her care. In most instances, recovery of neurological function is limited.

Patients with paraneoplastic cerebellar degeneration frequently exhibit serum and cerebrospinal fluid (CSF) antibody responses directed against neurons or other neuroglial populations, often with oligoclonal bands and other evidence of antibody synthesis within the central nervous system (CNS) [7]. Many of the known paraneoplastic antineuronal autoantibodies also react with patient tumors, and it is thought that the antineuronal antibody response seen in affected patients is elicited by tumor proteins immunologically similar to neuronal antigens [7]. Blood and CSF of patients with paraneoplastic neurological syndromes may also contain activated T lymphocytes reactive with the antigens recognized by the paraneoplastic autoantibody response [8–11].

Paraneoplastic and related neurological disorders fall into 2 groups: those characterized by an antibody response against intracellular neuronal proteins (Group 1), and those characterized by an antibody response directed against antigens expressed on neuronal membranes (Group 2) [11, 12]. Most patients with paraneoplastic cerebellar degeneration belong to Group 1: associated antibodies include anti-Yo (Purkinje cell antibody 1 or PCA1), found in patients with ovarian and breast malignancies; anti-Hu (Antineuronal nuclear antibody 1 or ANNA1), found in patients with small cell and neuroendocrine malignancies; anti-Ri (Antineuronal nuclear antibody 2 or ANNA2), found in patients with breast and small cell cancers; and anti-Tr, found in patients with Hodgkin’s disease (Table 1). A few cases have been reported, essentially all in patients with small cell lung neoplasms, with antibodies directed against anti-amphiphysin, anti-Zic4, and anti-Purkinje cell antibody 2 (PCA-2) (Table 1) [13].

Patients falling into Group 2 comprise only a minority of affected patients: these include patients with antibodies reactive with the metabotropic glutamate receptor subunit mGluR1, and antibodies to voltage gated calcium channels [14–16]. A small number of patients, most without identified cancer, develop ataxia in the setting of antibodies to glutamic acid decarboxylase (GAD) [17]. Unlike cases of limbic encephalitis associated with antibodies to cell membrane antigens [11, 12], patients with cerebellar degeneration associated with antibodies neuronal surface antigens often have underlying cancer and may be treatment-resistant.

Paraneoplastic cerebellar degeneration is an uncommon illness, and the rarity of the condition greatly complicates development of effective treatment [18]. Few individual institutions encounter enough patients to organize a prospective clinical trial, and multi-institutional collaborative studies employing standardized methods of diagnosis and treatment have not yet been reported. In most series, paraneoplastic cerebellar degeneration is included as a subset in treatment trials of a variety of paraneoplastic disorders. The majority of published reports have thus dealt with individual patients, and even the most extensive published articles—which are few in number—have been uncontrolled case series, often with internal variation in dose and duration of the treatments employed [18–22]. In many studies, treatment has been initiated weeks or months after the onset of symptoms, after irreversible cerebellar injury may already have occurred. In a study by Shams’ili et al only 63% of patients were still ambulatory at the time of neurological diagnosis [23].

To date no studies above the level of Class IV have been reported for paraneoplastic cerebellar degeneration. Three major approaches have been used in attempting to stabilize or reverse neurological injury in affected patients: modulation of paraneoplastic autoimmune response by immunosuppression or intravenous immunoglobulin G; removal of antibody by plasma exchange; or induction of tumor remission through surgery or chemotherapy.

## Treatment

### Pharmacological treatment

Pharmacological treatment of paraneoplastic neurological syndromes may be divided into 2 categories: treatment directed at patient symptoms
Table 1. Major autoantibodies associated with paraneoplastic cerebellar degeneration: characteristics and response to treatment

| Autoantibody                        | Antigenic targets within cerebellum | Association with neoplasia | Major associated neoplasms                                      | Response to immunomodulatory therapy | Response to tumor treatment |
|-------------------------------------|-------------------------------------|-----------------------------|----------------------------------------------------------------|--------------------------------------|------------------------------|
| Reactive with intracellular neuronal antigens |                                    |                             |                                                                |                                      |                              |
| Anti-Yo (APCA, PCA1)                | 34-kDa and 62-kDa Purkinje cell cytoplasmic proteins | Almost invariable           | Gynecologic and breast neoplasms                              | Poor                                 | Poor in most cases           |
| Anti-Hu (ANNA-1)                    | 35-kDa to 42-kDa proteins present in cytoplasm and nuclei of all neurons | Almost invariable           | Small cell carcinoma (usually lung), neuroendocrine tumors, myxoid chondrosarcoma | Improvement in occasional cases      | Improvement in occasional cases |
| Anti-Ri (ANNA-2)                    | 55-kDa proteins present in cytoplasm and nuclei of all neurons | Almost invariable           | Breast cancer, small cell lung carcinoma                      | Good in some patients               | Good in some patients        |
| Anti-Tr                             | Purkinje cell cytoplasm: delta/Notch-like epidermal growth factor-related receptor | Almost invariable           | Hodgkin’s disease                                              | Usually poor; improvement in rare cases | Usually poor; improvement in rare cases |
| Anti-PCA2                           | 280 kDa Purkinje cell cytoplasmic protein | Almost invariable           | Small cell lung cancer                                         | Usually poor                         | Usually poor                 |
| Anti-GAD\(^a\)                     | Purkinje cells                      | Uncommon                    | Thymoma, renal cell carcinoma, other small cell carcinoma (lung) | Good                                 | Unknown                      |
| Anti-Zic4                           | Cerebellar granule cells >> Purkinje or molecular layer neurons | Probably invariable         | Small cell carcinoma (lung)                                   | Poor                                 | Poor                         |
| Anti-mGluR1\(^a,b\)                | Purkinje cells, 2/3 reported cases  | 2/3 reported cases          | Hodgkin’s disease                                              | Stabilized in one case               | Unknown                      |
| Reactive with neuronal cell surface antigens\(^a\) | Purkinje and granule cells | Approximately 1/3 of patients | Small cell carcinoma (lung or other sites)                     | Poor in most cases                   | Poor                         |

\(^a\)May occur in patients without neoplasms
\(^b\)The metabotropic glutamate receptor mGluR1 is expressed intracellularly and is also expressed within dendritic spines and on neuronal cell membranes. The response of patients with this pattern of antibody response to treatment, however, more closely parallels that seen in patients with anti-Yo or anti-Hu antibodies. For this reason, anti-mGluR1 antibodies are included in Group 1

APCA anti-Purkinje cell antibody, PCA1 Purkinje cell autoantibody 1, GAD glutamic acid decarboxylase, GluR glutamate receptor subunit, mGluR metabotropic glutamate receptor subunit. (Adapted from Greenlee [18])
and immunomodulatory therapy directed against the underlying autoimmune process.

### Symptomatic treatment

Marked symptomatic improvement following treatment with clonazepam was described in a single patient with paraneoplastic cerebellar degeneration accompanying Hodgkin’s disease [24]. Apart from this 1 case, pharmacological treatment capable of improving cerebellar symptoms in affected patients have not been described.

### Immunotherapeutics

Reports of immunomodulatory or immunosuppressive therapy in paraneoplastic cerebellar degeneration are limited, and no controlled trial or even extensive series has been published. Published reports consist largely of retrospective individual cases, with only a few case series. In the majority of reported patients, immunomodulatory and/or immunosuppressive treatment is often combined with therapy directed at the underlying tumor, making it difficult to ascertain the role of either intervention. Most patients have been treated with corticosteroids, intravenous immunoglobulin G, and/or cyclophosphamide, singly, or in combination. Although clinical improvement has been reported following treatment in individual patients, most patients fail to improve [23, 25, 26]. Stark et al reported limited clinical improvement in 2 women with anti-Yo antibody response treated with cyclophosphamide [27]. Uchuya et al treated 22 patients with paraneoplastic syndromes, 4 of whom had paraneoplastic cerebellar degeneration associated with anti-Yo antibodies with between 1 and 11 courses of intravenous immunoglobulin G. [28]. Treatment was initiated 2–8 months following onset of symptoms. Functional status of these patients at initiation of treatment was not described. Improvement was not observed in any of the 4 patients [28]. Keime-Guibert et al treated 8 (7 with anti-Yo antibodies and 1 with anti-Hu) with 1–7 courses of combined intravenous immunoglobulin G (0.5 g/kg/day for 5 days) plus methylprednisolone (1 gram daily for 3 days) plus cyclophosphamide (600 mg/m2 given on day 4 of IV IgG), with additional treatments administered according to patient status [19]. Interval between onset of symptoms and treatment ranged between 2 weeks and 3 months in patients with anti-Yo antibody and was 10 months in the patient with anti-Hu antibody. Clinical stabilization was observed in 3 patients; 5 patients continued to progress [19]. Prognosis may be better in patients with anti-Ri antibody response and ataxia, where improvement has been reported in individual patients in response to treatment with corticosteroids, intravenous immunoglobulin G, or cyclophosphamide, along with treatment of the underlying tumor [29–32].

An important question is whether initiation of therapy early in the clinical course might improve prognosis. One of the patients treated with cyclophosphamide by Stark et al gained almost complete functional recovery following initiation of treatment 24 days after onset of symptoms [27]. Moll et al reported a patient with atypical antineuronal antibody
Corticosteroids

Standard dosage Treatment regimens have varied among clinical studies, but in general 2 approaches have been used: administration of intravenous methylprednisolone, 1,000 mg daily for 3–5 days, and use of prednisone at a dose of 60–80 mg daily for a period of time depending on its effect on disease. Frequently, intravenous methylprednisolone is used initially, to be followed by oral prednisone with eventual taper. In some instances high-dose intravenous methylprednisolone has also been used in repeating courses.

Main drug interactions Corticosteroids may decrease efficacy of live nasal influenza or other vaccines and may reduce efficacy of aldesleukin, mifepristone, and growth hormone. Use of corticosteroids is not recommended with natalizumab, alefacept, nevirapine, or telbivudine.

Main side effects Corticosteroids may induce hypertension. They frequently also alter glucose metabolism and diabetic control and may also, in occasional patients, produce mania or psychosis. Long-term use of corticosteroids may predispose to...
a variety of infections including oral candidiasis and can cause osteoporosis, aseptic necrosis of bone, diabetes, and cataracts. Pulse methylprednisolone is usually well-tolerated. In rare patients, however, infusion of methylprednisolone succinate has been followed by anaphylaxis.

Special points
Short-term use of high-dose methylprednisolone appears to have little immediate effect on immune function, as opposed to longer term use of oral prednisone.

Immunoglobulin G

Intravenous infusion of preparations of immunoglobulin G have been used successfully for myasthenia gravis, Lambert-Eaton myasthenic syndrome, and stiff-person syndrome. Its use in paraneoplastic cerebellar degeneration, however, is speculative. The mechanisms by which intravenous immunoglobulin G affects host immunity are not understood. Possible mechanisms include reduction of T cell proliferation and induction of lymphopenia; suppression of pro-inflammatory cytokines; induction of lymphocyte monocyte apoptosis; suppression of B cell differentiation; and endogenous immunoglobulin synthesis; and modulation of anti-idiotypic networks involved in immune tolerance [18, 38, 39].

Standard dosage
0.4 g/kg intravenously for 5 days to a total dose of 2 gm/kg. Courses of intravenous IgG can be repeated if necessary, usually as a course of 1–2 gm/kg. Several IgG preparations are commercially available, and dosage regimens differ somewhat among them. In general, however, infusion should begin at a rate of 0.01–0.02 ml/kg body weight per minute for 30 minutes. If this is well-tolerated, then the rate may be gradually increased to a maximum of 0.08 ml/kg body weight per minute. If the patient reacts adversely to the infusion, then the rate should be reduced, or the infusion halted, until symptoms subside [18]. In patients with limited or compromised acid-base compensatory mechanisms and in patients in whom there is already an expanded fluid volume (eg, during pregnancy), consideration should be given to the effect of additional fluid or protein load. Because administration and side-effect profiles may differ among IgG preparations, the treating physician should be familiar with the properties and side-effects profile of the preparation being used in a given patient [18].

Contraindications
Intravenous immunoglobulin G should not be administered to individuals who are known to have had an anaphylactic or severe systemic response to the agent. The agent should not be used in patients with selective IgG deficiencies who have known antibody against IgA (IgA antibody), since administration of may result in severe allergic reactions to IgA present in trace amounts.

Main drug interactions
Intravenous immunoglobulin G has little interaction with other drugs. Because of its effects on the immune system, however, it is recommended that live viral vaccines should not be given until approximately 6 months after immunoglobulin G administration.

Main side effects
Anaphylaxis may occur. In addition, a syndrome resembling anaphylaxis, including hypotension may occur, including in patients not known to be sensitive to the agent; this may be related to rate of infusion. Infusion reactions have also been reported. These may be characterized by symptoms of flushing, anxiety, abdominal cramps, myalgias, arthralgias, dizziness, fever, chills, headache, nausea, chest tightness, and fluctuations in blood
pressure, or heart rate. Some patients experience chronic malaise. Hypertension has been described during infusion. Intravenous immunoglobulin G has produced aseptic meningitis, with fever, headache, photophobia, nuchal rigidity [18]. Onset is usually within several hours to 2 days. CSF in these cases usually has a predominantly neutrophilic CSF pleocytosis with elevated protein and usually normal glucose. Recovery without sequelae usually occurs within several days after the infusions have been discontinued [40]. A study by Sekul et al suggests that patients with migraine may be at greater risk for this complication of the drug [40]. Work by Jayabose et al in children with immune thrombocytopenia suggests that pretreatment with corticosteroids may reduce the risk of meningitis [41]. Occasional patients may develop reversible renal insufficiency. Intravenous IgG increases blood viscosity, and thromboembolic events, including myocardial infarction, stroke, and intracranial venous sinus thrombosis, have been reported in up to 3% of patients [42–44].

Special points
The infusion should be given in a separate line not being used for fluids or other medications. Preparations of IgG from different manufacturers should not be combined [18]. Some preparations (e.g., Gamimune) may not be compatible with saline. Patients should be closely monitored during infusion for changes in vital signs or other evidence of adverse response to therapy. Epinephrine should be available to treat anaphylactic response.

Cyclophosphamide

An alkylating agent which cross-links DNA. The drug is a powerful and toxic immunosuppressive agent, which has profound effects on T lymphocyte function but may not affect titers of specific antibody in blood or CSF.

Standard dosage
1.5–3 mg/kg per day by mouth.

Contraindications
Cyclophosphamide is contraindicated during the pregnancy (Category D), during nursing, in patients with pre-existing bone marrow depression, leukopenia, thrombocytopenia, or renal or hepatic insufficiency. Cyclophosphamide is not to be used in patients receiving live virus vaccines.

Main drug interactions [18] Cyclophosphamide has significant additive effects when used with other immunomodulatory or immunosuppressive agents, drugs such as clozapine which are capable of causing myelosuppression, the folic acid antagonist pyrimethamine, and antiviral agents such as zidovudine [18]. Cyclophosphamide may also prolong succinylcholine-induced neuromuscular blockade. The drug may cause increased bleeding risk if used with warfarin. Inhibitors of the enzyme Cytochrome P450 3A4 (CYP3A4) inhibitors increase levels of cyclophosphamide. These include ritonavir and several other protease inhibitors used to treat HIV, antibiotics such as clarithromycin, chloramphenicol, or erythromycin, azole antifungal agents such as ketoconazole or voriconazole, and, to a lesser extent, calcium channel blockers such as verapamil or diltiazem.

Main side effects
These include anemia, leukopenia, and/or thrombocytopenia. Patients are at risk for hemorrhagic cystitis and for secondary malignancies, including carcinoma of the bladder, and are also susceptible to opportunistic infections. The agent may be associated with Stevens-Johnson syndrome. Nausea and vomiting are common and may be controlled with ondansetron. The drug may cause alopecia and/or stomatitis and, its use may result in amenorrhea or oligospermia. A syndrome of inappropriate antidiuretic hypersecretion
(SIADH) has been reported in individuals receiving doses of greater than 50 mg/kg or 1 g/m².

**Special points**

Patients should be aggressively hydrated to avoid hemorrhagic cystitis. Amount of drug given should be reduced by 25% in patients with a creatinine clearance of <10. In hemodialysis patients 50% of the standard drug dose should be given after each dialysis.

**Tacrolimus (FK506; prograf, astellas pharma)**

A macrolide immunosuppressive agent derived from the fungus, *Streptomyces tsukubaensis*. The drug inhibits T cell activation and IL-2 transription by preventing dephosphorylation of T cell calcineurin.

**Standard dosage**

Dosage in transplantation range from 0.075 to mg/kg/day to 0.1–0.2 mg/kg/day. In 1 study of its use in paraneoplastic cerebellar degeneration the drug was given at 0.15–0.30 mg/kg per day, in 2 divided oral doses, administered with 60 mg of prednisone daily [34••]. Tacrolimus was administered for no longer than 4 weeks, and prednisone was tapered over weeks 1–4 [34••].

**Contraindications**

Tacrolimus is contraindicated in patients with a hypersensitivity to the drug and in pregnancy or in nursing mothers. The injectable form of the agent is contraindicated in patients with a hypersensitivity to polyoxyl 60 hydrogenated castor oil.

**Main drug interactions**

As is the case with cyclophosphamide, blood levels of tacrolimus may be increased by CYP3A4 inhibitors (see above) and may be decreased by CYP3A4 inducers such as rifampin. The drug should not be used concomitantly with cyclosporine or sirolimus.

**Main side effects**

Tacrolimus has been associated with increased risk of infection, increased risk of malignancy, development of diabetes mellitus, hypertension, hyperkalemia, nephrotoxicity, and central neurotoxicity manifested as posterior reversible encephalopathy syndrome (PRES) [45–47]. Infections have included JC virus-induced progressive multifocal leukoencephalopathy (PML), BK virus-induced nephropathy, and cytomegalovirus infection. Malignancies have included lymphomas, post-transplant lymphoproliferative disorder, and cutaneous neoplasms. Risk of developing diabetes mellitus appears higher in Hispanic and African-American patients. Tacrolimus has also been associated with cardiac hypertrophy and with pure red cell aplasia.

**Special points**

Trough concentrations of tacrolimus should be carefully monitored. Live virus vaccines should not be administered to patients receiving tacrolimus. Patients receiving tacrolimus should not drink grapefruit juice. Tacrolimus is typically given in combination with corticosteroids.

**Rituximab**

Rituximab (Roche Ltd, Basel, Switzerland) is a chimeric monoclonal agent which consists of human IgG1 constant regions and murine variable regions. The agent is specific for CD20, a transmembrane protein which is expressed on pre-B lymphocytes and B cells but not on plasma cells. CD20 is important in B-cell activation, proliferation, and differentiation [48]. Rituximab is currently approved for treatment of B cell (non-Hodgkin’s) lymphoma and rheumatoid arthritis and has been found to be of value in treatment of multiple sclerosis [49]. The agent has reduced B cells in both blood and CSF, with B cell numbers remaining depressed for between 3 and 12 months [50, 51]. In studies of children with opsoclonus-myoclonus
treated with rituximab, Prazatelli et al found that CSF B cell populations (including CD27+ memory, CD38+ activated, and CD5+ subsets) remained significantly depressed in CSF for 12–18 months despite repopulation of these cells in blood [52]. Although CD20 is not expressed on plasma cells, Petereit et al have reported depletion of plasma as well as B cells from both serum and cerebrospinal fluid of a patient treated with rituximab [51]. However, despite its effect on B lymphocytes, rituximab may fail to reduce titers of specific antibody in serum or CSF [36, 51]. Only limited use of the agent has thus far been reported in paraneoplastic cerebellar degeneration. In an uncontrolled study of 9 patients with paraneoplastic neurological syndromes treated with rituximab, Shams’ili et al reported clinical improvement in 1 patient with paraneoplastic cerebellar degeneration associated with anti-Yo antibodies [36]. Yeo et al reported substantial improvement in cerebellar symptoms following treatment with rituximab in a pediatric patient with Hodgkin’s disease after chemotherapy for the malignancy failed to produce neurological improvement [37•]. A closely related humanized monoclonal, ocrelizumab, has been shown of value in treatment of multiple sclerosis, but its use has not yet been reported in paraneoplastic neurological disease [53, 54].

**Standard dosage**
A standard dosage regimen for use of rituximab in paraneoplastic disorders has not yet been established. Treatment of neuromyelitis optica has employed regimens of 375 mg/M² for up to 4 infusions given at 4 week intervals or, alternatively, 1,000 mg infused twice with 2 weeks between infusions [55]. Use in paraneoplastic cerebellar degeneration has involved a regimen of 375 mg/M² for up to 4 infusions given at 4 week intervals [36].

**Contraindications**
Rituximab is contraindicated in patients with allergy to mouse proteins and should be used with caution in elderly individuals, patients with a history of cardiac disease (angina or cardiac arrhythmias), cancer patients with high tumor burden, patients receiving cisplatin, or patients with known chronic infections including hepatitis B. There is increased risk of infusion reactions in patients with pulmonary conditions.

**Main drug interactions**
The use of live virus vaccines, including nasal influenza vaccines, is contraindicated, as is simultaneous treatment with natalizumab or TNF blocking agents. Concomitant use of antihypertensive agents during infusion may exacerbate hypotension.

**Main side effects**
The drug has been associated with fatal infusion reaction complex (hypoxia, pulmonary infiltrates, ARDS, MI, ventricular fibrillation, and/or cardiogenic shock), and PRES [56]. Post-exposure side effects in the weeks following infusion may include tumor lysis syndromes with renal failure, Stevens-Johnson syndrome, and severe mucocutaneous reactions [18]. Neutropenia has been reported as a late complication of therapy [57]. Bowel obstruction and perforation have been reported, as has renal toxicity, and sensory neuropathy. A variety of infectious complications may arise, in the months following infusion. These have included reactivation of hepatitis B, progressive multifocal leukoencephalopathy (JC virus), and infections with West Nile virus, hepatitis C, herpes simplex virus, cytomegalovirus, and parvovirus B19 [58–60]. It should be noted that many of the patients developing opportunistic infections have also been on other immunosuppressive agents.
Special points

Patients should be premedicated with an antihistamine (usually Benadryl) and acetaminophen 30 minutes prior to dosing and should be closely monitored during the infusion. Patients may require treatment with methylprednisolone 100 mg IV or its equivalent 30 minutes prior to each infusion. Infusion reactions may require Benadryl, intravenous fluids, glucocorticoids, epinephrine, bronchodilators, or oxygen. Infusion reaction can usually be managed by slowing the rate by at least 50%. Although unusual in paraneoplastic disorders, patients with high numbers of circulating malignant cells (≥25,000/mm³) may be at increased risk for tumor lysis syndrome. Ocrelizumab, a humanized monoclonal with specificity similar to rituximab, has not yet been studied in paraneoplastic cerebellar degeneration but may an alternative agent in patients allergic to mouse proteins.

Mycophenolate mofetil

Mycophenolate mofetil (CellCept) is converted to mycophelolic acid (MPA) after ingestion. MPA targets inosine monophosphate dehydrogenase, a rate-limiting enzyme in de novo synthesis of guanosine nucleotides essential for DNA synthesis [45, 61]. The enzyme plays a particularly important role in T- and B-lymphocytes and is 5-fold more potent in inhibiting the isoform of inosine monophosphate dehydrogenase found in activated lymphocytes compared with the isoform found in most other cells [61]. The agent induces apoptosis of activated lymphocytes and may also reduce lymphocyte recruitment by suppressing expression of adhesion molecules and suppressing production of inducible nitric oxide synthetase (iNOS). MPA also suppresses primary (but not secondary) antibody responses [61]. Mycophenolate mofetil has received extensive use in myasthenia gravis [62, 63] and has been used, often in combination with prednisone, in treatment of limbic encephalitis associated with antibodies to neuronal surface antigens [64–67]. Its use has not been reported in proven paraneoplastic cerebellar degeneration, but it has been used to induce disease stabilization in 1 patient with mGluR1-associated cerebellitis in whom no tumor was found [16].

Standard dosage

Mycophenolate mofetil is usually given as 1,000–1,500 mg twice daily.

Contraindications

The drug is contraindicated in patients who are hypersensitive to the agent, during pregnancy, and in patients with Lesch-Nyhan syndrome or Kelly Seegmiller syndrome. The agent is used with caution in elderly patients or in patients with severe gastrointestinal or renal disease, or in patients who have depressed bone marrow function.

Main drug interactions

The use of live virus vaccines is contraindicated, as is simultaneous treatment with natalizumab or TNF blocking agents. Increased free blood levels of MPA may occur in patients treated with agents which compete with MPA for albumen binding, such as phenytoin, xanthine bronchodilating agents, and salicylic acid. Absorption of the mycophenolate mofetil may be inhibited by antacids containing aluminum or magnesium and by cholestyramine or protein pump inhibitors. Antibiotics, including macrolides, cephalosporins, penem antibiotics, penicillins, and sulfonamides may decrease MPA blood levels by inhibiting enterohepatic circulation of the drug. Blood levels of MPA may be increased in patients taking probenecid, acyclovir, gancyclovir, or valgancyclovir.
Main side effects

The most common side effects include gastrointestinal symptoms of diarrhea, nausea, or vomiting; these symptoms may occasionally be severe. Some patients may develop elevated liver transaminases. The drug may produce leukopenia or, less frequently, anemia, or thrombocytopenia. Both the gastrointestinal and hematological side effects of mycophenolate mofetil may resolve with continued treatment. The drug has been associated with pure red cell aplasia; this has been reported to resolve upon discontinuation of the drug. A variety of opportunistic viral, bacterial, mycobacterial, and fungal infections has been reported in patients receiving the drug [45, 68–73]. Many of these patients have received prior or concomitant treatment with other immunosuppressive agents [45, 68–73].

Special points

Complete blood count, liver function tests, and creatinine should be obtained prior to beginning the drug, then weekly for 1 month (or longer if dosage of the drug is increased after that time), then twice monthly for 2 months, and then monthly for the first year. Serum creatinine and liver function tests may be checked every 2–3 weeks initially and during dose escalation, and then every 2–3 months once stable dosage is reached [45].

Interventional procedures

Plasma exchange

Therapeutic plasma exchange involves a process of blood purification using an extracorporeal device designed to remove particles of large molecular weight from plasma [18, 74]. The process removes antibodies and immune complexes nonspecifically and also removes cytokines and other mediators of inflammation [74]. The procedure has been of value in treatment of autoimmune neurological disorders associated with antibodies directed against cell membrane components [11, 12]. However, it does not reliably remove IgG from cerebrospinal fluid [75, 76]. Although individual cases of clinical improvement have been reported following plasma exchange in patients with paraneoplastic disorders [5, 22, 77], most patients have failed to improve [18, 22, 24, 78–81].

Standard procedure

Different investigators have used a wide range of protocols. A reasonable regimen would be a course of 5–6 exchanges of 1–1.25 plasma volumes carried out over 10–14 days [82]. Vernino et al in their study of plasma exchange and other modalities in patients with paraneoplastic disorders employed 1 plasma volume exchange every other day for a total of 5 exchanges [18, 22].

Contraindications

Plasma exchange is contraindicated in patients with precarious hemodynamic status (eg, cardiogenic shock), unstable angina pectoris, or pericardial effusions) [18]. The procedure is also contraindicated in patients with uncontrollable sepsis or septic shock.

Complications

In a prospective study, the most common adverse effects were fever (7.1 % of patients); hypocalcemic symptoms including paresthesias, and muscle cramps (8.2 %) due to infused citrate; mild hypotension (8.1 %); nausea (4.7 %), vomiting (4.1 %), and tachycardia (4.4 %) [18,
Severe hypotension was noted in 2.2% of patients. Urticaria and pruritus were more common in patients receiving fresh frozen plasma. Complication rates were higher in patients who were significantly anemic [83]. Risk of infection due to vascular access and reduction in immunoglobulins and complement is a significant concern. Hypocoagulable states may occur, usually during a period from 8–12 hours after exchange. Subsequently (usually between 24 and 72 hours) a rebound hypercoagulable state due to delayed recovery of antithrombin 3 levels may rarely occur and may require treatment with heparin.

**Surgical and medical treatment of the underlying neoplasm**

Therapy directed against the underlying tumor is of fundamental importance not only because of the need to deal with the cancer itself, but also because of its potential effect on progression of the paraneoplastic disorder [20–22]. Candler et al in a study in which patients with paraneoplastic neurological syndromes were followed over time, found that treatment of the underlying tumor, with or without immunosuppressive therapy, was the only measure which was associated with stable or improved neurological condition [21]. Likelihood of improvement or stabilization of paraneoplastic neurological syndromes may depend the duration of paraneoplastic symptoms prior to tumor remission and on the specific autoantibody involved. Clinical outcome appears to be poorest in patients with anti-Yo, anti-Hu, anti-Tr, and anti-mGluR1 antibodies but significantly better in patients with anti-Ri antibody [23]. Partial remission in cerebellar symptoms was reported in 3/3 patients undergoing successful treatment of Hodgkin’s disease [84].

**Emerging therapies and future directions**

- Therapies specifically designed for treatment of paraneoplastic cerebellar degeneration are not available. For the foreseeable future, treatment of these disorders will involve off-label use of agents designed for other disorders.
- Overall, therapies designed to depress T cell-mediated immunity, including tacrolimus, have had, at best, marginal success. Most treatments used have had, at best, variable effect on antibody titers.
- Early, uncontrolled studies with rituximab are relatively promising, but larger numbers of patients need to be studied in controlled fashion. Use of other monoclonal immunosuppressive drugs has not been reported. Agents such as bortezomib, which affects plasma cells directly, may warrant investigation [85, 86].
- Rapid diagnosis and institution of treatment are essential to prevent irreversible neurological injury, and the clinician may need to begin immunosuppressive therapy on strong clinical suspicion while awaiting results of studies to detect antineuronal antibodies.
- There remains a great need for multi-institutional controlled studies instituting treatment early in disease and employing standardized
methods for diagnosis, strictly regulated treatment protocols, and uniform criteria for follow-up.

Acknowledgments

Dr. Greenlee has received grant support from the US Department of Veterans Affairs. This article is an update of the article written by Dr. Greenlee and published in Current Treatment Options in Neurology (“Treatment of Paraneoplastic Neurologic Disorders”) in 2010 (volume 12, issue 3).

Disclosure

No potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Henson RA, Urich H. Cortical cerebellar degeneration. In: Henson RA, Urich H, editors. Cancer and the nervous system: the neurological manifestations of systemic malignant disease. Oxford: Blackwell Scientific Publications; 1982. p. 346–67.

2. Brain WR, Daniel PM, Greenfield JG. Subacute cortical cerebellar degeneration and its relation to cancer. J Neurol Neurosurg Psychiatry. 1951;14:59–75.

3. Greenfield JG. Subacute cerebellar degeneration associated with neoplasms. Brain. 1934;57:161–76.

4. Brain L, Wilkinson M. Subacute cerebellar degeneration associated with neoplasms. Brain. 1965;88:465–78.

5. Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42:1931–7.

6. Greenlee JE, Dalmau J, Lyons T, et al. Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue, and fall in antibody titers following tumor removal. Ann Neurol. 1999;45:805–9.

7. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–40.

8. Pellkofer HL, Voltz R, Goebels N, et al. Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol. 2009;66:655–8.

9. Pellkofer H, Schubart AS, Hofberger R, et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeural antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain. 2004;127:1822–30.

10. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47:9–17.

11. Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135:1622–38.

12. Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83:638–45.

13. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2009;509–17.

14. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997;120:1279–300.

15. Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342:21–7.

16. Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol. 2010;67:627–30.

17. Honnorat J, Trouillas P, Thivolet C, et al. Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements. Arch Neurol. 1995;52:462–8.
21. Candler PM, Hart PE, Barnett M, et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry. 2000;68:479–82.
22. Vernino S, O’Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-Oncol. 2004;6:55–62.
23. Shams’ili S, Greffens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409–18.
24. Hammad I, Kotanides H, Rosenblum MK, et al. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin’s disease. Neurology. 1992;42:1938–43.
25. Poepel A, Jarius S, Heukamp LC, et al. Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome. J Neurol Sci. 2007;263:145–8.
26. Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol. 2006;253 Suppl 5:V33–8.
27. Stark E, Wurster U, Patzgold U, et al. Immunologial and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995;52:814–8.
28. Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60:388–92.
29. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsonoclonus-myoclonus. Brain. 2001;124:437–43.
30. Luque FA, Furneaux HM, Feziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsonoclonus and breast cancer. Ann Neurol. 1991;29:241–51.
31. Digre KB. Opsonoclonus in adults: report of 3 cases and review of the literature. Arch Neurol. 1986;43:1165–75.
32. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580–7.
33. Moll JWB, Henzen-Logmans SC, Van der Merche FGA, et al. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration [letter]. J Neurol Neurosurg Psychiatry. 1994;56:112.
34. Orange D, Frank M, Tian S, et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol. 2012;69:1132–40.
This recent article details the use of the immunosuppressive agent, tacrolimus, in treatment of paraneoplastic disorders including paraneoplastic cerebellar degeneration. The article outlines a carefully considered approach to treatment. However, the drug had only limited effectiveness in the population studied.
35. Esposito M, Penza P, Orefice G, et al. Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol. 2008;86:363–4.
36. Shams’ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253:16–20.
37. Yeo KK, Walter AW, Miller RE, et al. Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Pediatr Blood Cancer. 2012;58:986–7.
This recent single case report also suggests a possible role for rituximab in the treatment of paraneoplastic cerebellar degeneration.
38. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. New Engl J Med. 2012;367:2015–25.
39. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102–7.
40. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62.
41. Jayabose S, Mahmoud M, Levendoglu-Tugal O, et al. Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1999;21:514–7.
42. Evangeliou N, Littlewood T, Anslow P, et al. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol. 2003;56:308–9.
43. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223–6.
44. Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci. 2003;24 Suppl 4:S222–6.
45. Zwerener J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007;20:229–38.
46. Watorek E, Boratynska M, Smolska D, et al. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011;16:14–8.

47. Cowlick I, Delventhal H, Kaipainen K, et al. Three-year follow-up of malignancies in tacrolimus-treated renal recipients—an analysis of European multicenter studies. Clin Transplant. 2008;22:372–7.

48. Graves D, Vernino S. Immunotherapies in neurologic disorders. Med Clin N Am. 2012;96:497–523.

49. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.

50. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70.

51. Peterit HF, Moeller-Hartmann W, Reske D, et al. Rituximab in a patient with multiple sclerosis—effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand. 2008;117:399–403.

52. Pranzatelli MR, Tate ED, Travelstead AL, et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric Ospoclonus-Myoclonus. J Clin Immunol. 2010;30:106–13.

53. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicenter trial. Lancet. 2011;378:1779–87.

54. Fernandez O, Alvarez-Cermen JC, Arroyo-Gonzalez R, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol. 2012;54:734–49.

55. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443–8.

56. Min L, Zwerling J, Ocaya LC, et al. Reversible posterior leukoencephalopathy in connective tissue diseases. Semin Arthritis Rheum. 2006;35:388–95.

57. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19:32–8.

58. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.

59. Sharma M, Moore J, Nguyen V, et al. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009;84:614–6.

60. Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2009;24:223–8.

61. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.

62. Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41:593–8.

63. Hanisch F, Wendt M, Zierz S. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis—a long-term prospective open-label study. Eur J Med Res. 2009;14:364–6.

64. Mirabelli-Badenier M, Morana G, Pinto F, et al. Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia. Arch Neurol. 2012;69:1064–6.

65. Cornelius JR, Pittcock SJ, McKeon A, et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68:733–8.

66. Saidha S, Murphy S, Ronayne A, et al. Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil. J Neurol. 2010;257:1035–8.

67. Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry. 2010;81:1167–9.

68. Hegde S, Annamalai R, Biswas J. Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis. J Ophthalmic Inflamm Infect. 2012;2:47–8.

69. Sato A, Amada N, Kikuchi H, et al. Pneumonia due to varicella-zoster virus reinfection in a renal transplant recipient. Transplant Proc. 2009;41:3959–61.

70. Lauzurica R, Bayes B, Frias C, et al. Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant Proc. 2003;35:1758–9.

71. Eisen HH, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517–25.

72. Pavlovic AM, Bonaci-Nikolic B, Kozic D, et al. Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus. 2012;21:100–2.

73. Tamaki H, Kawakami M, Ikegane K, et al. Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation. Int J Hematol. 2004;80:291–4.

74. Lehmann HC, Hartung HP, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006;63:930–5.
75. Graus F, Abos J, Roquer J, et al. Effect of plasmapheresis on serum and CSF autoantibody levels in CNS paraneoplastic syndromes. Neurology. 1990;40:1621–3.

76. Furneaux HM, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 1990;40:1085–91.

77. David YB, Warner E, Levitan M, et al. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer. 1996;78:2153–6.

78. O'Brien TJ, Pasaliaris B, D'Apice A, et al. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of 3 cases and review of the literature. J Clin Neurosci. 1995;2:316–20.

79. McCrystal M, Anderson NE, Jones RW, et al. Paraneoplastic cerebellar degeneration in a patient with chemotherapy-responsive ovarian cancer. Int J Gynecol Cancer. 1995;5:396–9.

80. Cehreli C, Payzin B, Undar B, et al. Paraneoplastic cerebellar degeneration in association with Hodgkin’s disease: a report of 2 cases. Acta Haematol. 1995;94:210–3.

81. Blumenfeld AM, Recht LD, Chad DA, et al. Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology. 1991;41:1682–5.

82. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher. 2000;15:74–128.

83. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22:270–6.

84. Schlake HP, Husstedt IW, Grotemeyer KH, et al. Paraneoplastic subacute cerebellar degeneration in Hodgkin’s disease. Report of 3 cases and review of the literature. Clin Neurol Neurosurg. 1989;91:329–35.

85. Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2012;13:729-36.

86. Gomez AM, Vrolix K, Martinez-Martinez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol. 2011;186:2503–13.